Recommendations of an international task force. Ann Rheum Dis (2023)

Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis (0)

by Smolen JS

Tools

Sorted by:

Results 1 - 10 of 31

Next 10 →

(Video) The updated EULAR management recommendations for RA in light of most recent developments Josef Smole

JR: Thresholds in Disease Activity for Switching Biologics in RA Patients: Experience from a Large United States Cohort

by Jie Zhang, Ying Shan, George Reed, Joel Kremer, Jeffrey D, Scott Baumgartner, Jeffrey R Curtis - Arthritis Care Res (Hoboken

"... Objective—The study aims to examine the threshold in disease activity associated with switching biologic treatment regimens in RA patients in real-world clinical practice. Methods—Using data from a prospective observational North American cohort of RA patients through 12/30/2009, patients who initia ..."

Abstract - Cited by 2 (0 self) - Add to MetaCart

Objective—The study aims to examine the threshold in disease activity associated with switching biologic treatment regimens in RA patients in real-world clinical practice. Methods—Using data from a prospective observational North American cohort of RA patients through 12/30/2009, patients who initiated a new anti-TNF agent with ≥ 6 months of follow-up were identified. Patients were classified as switchers or maintainers depending on whether they continued their anti-TNF treatment or switched (including discontinuation) within 12 months. Level of disease activity measured by CDAI and DAS28 at time of switch (corresponding follow-up visit for maintainers) was examined and random effect multivariable logistic regression was used to adjust for covariates. Results—Mean age and RA duration among 1,549 eligible patients were 56.1 and 9.6 years, 80 % were women, 62 % were initiating their 1st biologic and 30 % 2nd. At time of switch, the median DAS28 and CDAI were 3.1 and 8.4 among maintainers, and 4.0 and 15.2 among switchers. Maintainers also experienced a greater amount of reduction in disease activity compared with switchers (CDAI: −7.7 vs. −2.3; DAS28: −1.1 vs. −0.3). The threshold to switch

(Show Context)

Identification and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein. PLoS One. 2013;8(5):e63073. • We accept pre-submission inquiries • Our selector tool helps you to find the most relevan

by Yuki Kuroiwa, Yoichi Takakusagi, Tomoe Kusayanagi, Kouji Kuramochi, Takahiko Imai, Tomoko Hirayama, Ichiaki Ito, Michiteru Yoshida, Kengo Sakaguchi, Fumio Sugawara

"... Background: Methotrexate (MTX) is an agent used in chemotherapy of tumors and autoimmune disease including rheumatoid arthritis (RA). In addition, MTX has some anti-inflammatory activity. Although dihydrofolate reductase (DHFR) is a well-known target for the anti-tumor effect of MTX, the mode of act ..."

Abstract - Cited by 1 (0 self) - Add to MetaCart

Background: Methotrexate (MTX) is an agent used in chemotherapy of tumors and autoimmune disease including rheumatoid arthritis (RA). In addition, MTX has some anti-inflammatory activity. Although dihydrofolate reductase (DHFR) is a well-known target for the anti-tumor effect of MTX, the mode of action for the anti-inflammatory activity of MTX is not fully understood. Methodology/Result: Here, we performed a screening of MTX-binding proteins using T7 phage display with a synthetic biotinylated MTX derivative. We then characterized the interactions using surface plasmon resonance (SPR) analysis and electrophoretic mobility shift assay (EMSA). Using a T7 phage display screen, we identified T7 phages that displayed part of high-mobility group box 1 (HMGB1) protein (K86-V175). Binding affinities as well as likely binding sites were characterized using genetically engineered truncated versions of HMGB1 protein (Al G1-K87, Bj: F88-K181), indicating that MTX binds to HMGB1 via two independent sites with a dissociation constants (KD) of 0.5060.03 mM for Al and 0.2460.01 mM for Bj. Although MTX did not inhibit the binding of HMGB1 to DNA via these domains, HMGB1/RAGE association was impeded in the presence of MTX. These data suggested that binding of MTX to part of the RAGE-binding region (K149-V175) in HMGB1 might be significant for the anti-inflammatory effect of MTX. Indeed, in murine macrophage-like cells (RAW 264.7), TNF-a release and mitogenic activity elicited by specific RAGE stimulation with a truncated monomeric HMGB1 were inhibited in

(Show Context)

(Video) The British Society for Rheumatology’s Choosing Wisely UK Recommendations

PADI4 and HLADRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study. PLoS One 8: e61045

by Taku Suzuki, Katsunori Ikari, Koichiro Yano, Eisuke Inoue, Yoshiaki Toyama, Atsuo Taniguchi, Hisashi Yamanaka, Shigeki Momohara , 2013

"... Introduction: Rheumatoid arthritis (RA) is a systemic, chronic inflammatory disease influenced by both genetic and environmental factors, leading to joint destruction and functional impairment. Recently, a large-scaled GWAS meta-analysis using more than 37,000 Japanese samples were conducted and 13 ..."

Abstract - Cited by 1 (0 self) - Add to MetaCart

Introduction: Rheumatoid arthritis (RA) is a systemic, chronic inflammatory disease influenced by both genetic and environmental factors, leading to joint destruction and functional impairment. Recently, a large-scaled GWAS meta-analysis using more than 37,000 Japanese samples were conducted and 13 RA susceptibility loci were identified. However, it is not clear whether these loci have significant impact on joint destruction or not. This is the first study focused on the 13 loci to investigate independent genetic risk factors for radiographic progression in the first five years from onset of RA.

Treating Rheumatoid Arthritis to Target: A Canadian Physician Survey

by Carter Thorne, John Wade, Boulos Haraoui, William Bensen, Louis Bessette, Sharon Le Clercq, Carter Thorne, John Wade

"... 2. Information on Subscriptions ..."

Abstract - Add to MetaCart

2. Information on Subscriptions

Editorial A Rheumatologist Managing Patients with Rheumatoid Arthritis: An Artisan But Also

by Maxime Dougados, J Rheumatol, An Artist

"... 3. Have us contact your library about access options ..."

Abstract - Add to MetaCart

3. Have us contact your library about access options

(Video) How are EULAR recommendations developed? example of ASAS EULAR axSpa recommendations 2022 update

Contents lists available at SciVerse ScienceDirect

by unknown authors

"... 4Cost implications of self ..."

Abstract - Add to MetaCart

4Cost implications of self

(Show Context)

S a b c

by E Departments Of Radiology, Tephanie Wilsone, Joel Petersson F, Remo Panaccioneg

"... improving patie bowel diseases ..."

Abstract - Add to MetaCart

improving patie bowel diseases

Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial

by S. Cofield, Larry W. Morel, S. Louis Bridges, Veena K. Ranganath, Jeffrey R. Curtis, Theresa Mcvie, Ted R. Mikuls, Richard J. Reynolds, Iris Navarro-millán, J Rheumatol, Jeffrey R. Curtis, Theresa Mcvie, Ted R. Mikuls, Richard J. Reynolds, Iris Navarro-millán, Larry W. Morel, S. Louis, Veena K. Ranganath, Stacey S. Cofield

"... 2. Information on Subscriptions ..."

Abstract - Add to MetaCart

2. Information on Subscriptions

(Video) RNL 2021 - EULAR 2019 and ACR 2020 RA Treatment Guidelines - Dr. Alan Matsumoto

Phase of Disease-modifying Antirheumatic Drug (DMARD) Use in Patients with Arthritis Who Recently Started Their First DMARD Treatment

by Johanna M. W. Hazes, Annelieke Pasma, Adriaan Van't Spijker, A J. Luime, Margot J. M. Walter, Jan J. V, Annelieke Pasma, Adriaan Van ’t Spijker, A J. Luime, Margot J. M. Walter, Jan J. V. Busschbach, Johanna M. W. Hazes

"... 2. Information on Subscriptions ..."

Abstract - Add to MetaCart

2. Information on Subscriptions

(Show Context)

Resonance Imaging in Patients with Rheumatoid Arthritis in Remission

by Joan Maymó, Maria Pilar Lisbona, Anna Pàmies, Jesús Ares, Miriam Almirall, Maria Navallas, J Rheumatol, Maria Pilar Lisbona, Anna Pàmies, Jesús Ares, Miriam Almirall, Maria Navallas, Albert Solano, Joan Maymó

"... 2. Information on Subscriptions ..."

Videos

1. Medicine Grand Rounds: "Updates in Rheumatology" 3/30/21
(Emory Department of Medicine)
2. Multistakeholder Workshop on EMA’s extended mandate session 3
(European Medicines Agency)
3. Dr Tanuja Chitnis - Treating paediatric MS in the modern era
(At the Limits - Leading Medical Education)
4. Policy Dialogue | The Revision of the EU Regulations on Medicines for Children and Rare Diseases
(EuroCancerLeagues)
5. Nuevas Estrategias Terapéuticas en Lupus
(Daniel Xibille Friedmann)
6. TNR Grand Rounds - Evaluation of Febrile Rheumatic Patients
(RheumNow)
Top Articles
Latest Posts
Article information

Author: Merrill Bechtelar CPA

Last Updated: 02/09/2023

Views: 6432

Rating: 5 / 5 (50 voted)

Reviews: 81% of readers found this page helpful

Author information

Name: Merrill Bechtelar CPA

Birthday: 1996-05-19

Address: Apt. 114 873 White Lodge, Libbyfurt, CA 93006

Phone: +5983010455207

Job: Legacy Representative

Hobby: Blacksmithing, Urban exploration, Sudoku, Slacklining, Creative writing, Community, Letterboxing

Introduction: My name is Merrill Bechtelar CPA, I am a clean, agreeable, glorious, magnificent, witty, enchanting, comfortable person who loves writing and wants to share my knowledge and understanding with you.